Nabla Bio
YC S20Boston, US · Founded 2020 · 8 employees · 8 known investors
Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.
Also known as Inc.
AI & Machine LearningBiotechDeep TechHealthtechAI-powered Drug DiscoveryUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S20)
Nabla Bio was founded in 2020 by Surge Biswas and Frances Anastassacos.
SB
Surge Biswasin𝕏Co-founder & CEOSurge Biswas has over a decade of experience applying synthetic biology and machine learning to biological engineering. He recently earned a PhD from Harvard University under George Church.
FA
Frances AnastassacosinCofounderFrances Anastassacos holds a PhD in Biological Sciences from Harvard University (2019) and has eight years of experience in synthetic biology and chemistry applied to biological systems. She has worked in biotech venture capital before founding Nabla Bio.
Investors · 8
Cantos VenturesSan Francisco · $400K – $1.5M
Fifty YearsSan Francisco · $250K – $2M
Pillar VCBoston · $50K – $4M
Radical VenturesToronto · $1M – $25M
Y CombinatorSan Francisco · $500K
Zetta Venture PartnersSan Francisco · $1M – $5M
Boom Capital VenturesreportedSan Francisco · $50K – $300Kvia Celestine Schnugg · inferred
Khosla Venturesreported · 2 sourcesMenlo Park · $5K – $50M
Funding
SEC filings, press & company announcements$26M disclosed across 1 round · 2024
- $26MSeries AMay 2024 · 3 sources
Radical Ventures (lead), Khosla Ventures, Zetta Venture Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlap
Day One Biopharmaceuticals17 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Alnylam13 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Companies competing with Nabla Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nabla Bio do?
- Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.
- Who founded Nabla Bio?
- Nabla Bio was founded by Surge Biswas, Frances Anastassacos in 2020.
- Who are Nabla Bio's investors?
- Nabla Bio's investors include Cantos Ventures, Fifty Years, Pillar VC, Radical Ventures, Y Combinator, Zetta Venture Partners, Boom Capital Ventures, Khosla Ventures.
- How much funding has Nabla Bio raised?
- Nabla Bio has disclosed $26M raised across 1 round.
- Where is Nabla Bio headquartered?
- Nabla Bio is headquartered in Boston, US.